US 12042558
Method and formulation for improving roflumilast skin penetration lag time
granted A61KA61K31/122A61K31/17
Quick answer
US patent 12042558 (Method and formulation for improving roflumilast skin penetration lag time) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/122, A61K31/17, A61K31/194, A61K31/366